SFI
ACRS icon

Susquehanna Fundamental Investments’s Aclaris Therapeutics ACRS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,316
Closed -$44.9K – 715
2025
Q1 		$44.9K Buy
+29,316
New +$62.5K ﹤0.01% 1042

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Susquehanna Fundamental Investments's ACRS Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 29,316 shares — an estimated $44.9K sold.

Susquehanna Fundamental Investments first reported a position in ACRS in Q1 2025 and held it in 1 quarter. The position peaked at $44.9K in Q1 2025. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 29,316 Aclaris Therapeutics shares in Q2 2025, an estimated $44.9K.
  • Susquehanna Fundamental Investments first reported a position in Aclaris Therapeutics in Q1 2025 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Aclaris Therapeutics position peaked at $44.9K in Q1 2025.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.